All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Practice-changing abstracts at ASCO and EHA 2020

GvHD Hub Co-Chair Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne Université, Paris, FR, provides an overview of the practice-changing abstracts from this year's virtual American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Annual Congress.

Practice-changing abstracts at ASCO and EHA 2020

Mohamad Mohty highlights 2020 as a major year for GvHD. In particular, 2020 saw the publication of the first positive phase III trial for steroid-refractory GvHD.